Model List of Essential Medicines

Abemaciclib

Section	Indications
Targeted therapies	Therapeutic equivalent to palbociclib for Other specified malignant neoplasms of breast

Abiraterone

Section	Indications
Hormones and antihormones Oral > Solid: 250 mg; 500 mg	Malignant neoplasms of prostate

Adalimumab

Section	Indications
Immunomodulators for non-malignant disease Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL	Axial spondyloarthritis Crohn disease site Rheumatoid arthritis

Afatinib

Section	Indications
Targeted therapies	Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung

All-trans retinoic acid

Section	Indications
Targeted therapies Oral > Solid: 10 mg capsule	Acute myeloid leukaemia with recurrent genetic abnormalities

Allopurinol

Section	Indications
Supportive medicines Oral > Solid: 100 mg; 300 mg	Tumour lysis syndrome

Anastrozole

Section	Indications
Hormones and antihormones Oral > Solid: 1 mg tablet	Other specified malignant neoplasms of breast Malignant neoplasms of breast

Arsenic trioxide

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion	Acute myeloid leukaemia with recurrent genetic abnormalities

Asparaginase

Section	Indications
Cytotoxic medicines Powder for injection: 10 000 IU in vial. Parenteral > General injections > unspecified: 10000 IU in vial powder for injection	Unspecified malignant neoplasms of ill-defined or unspecified sites Lymphoid leukaemia, not elsewhere classified

Atezolizumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion	Other specified malignant neoplasms of bronchus or lung Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung

Axicabtagene ciloleucel

Section	Indications
Antineoplastics and supportive medicines Cell suspension for infusion: 2 × 10*6 anti-CD19 CAR-positive viable T-cells per kg of body weight.	Diffuse large B-cell lymphomas

Azacitidine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 100 mg in vial powder for injection	Myeloid leukaemia

Azathioprine

Section	Indications
Immunomodulators for non-malignant disease Parenteral > General injections > IV: 50 mg in vial powder for injection (as sodium salt); 100 mg in vial powder for injection (as sodium salt) Oral > Liquid: 10 mg per mL Oral > Solid > tablet: 25 mg; 50 mg (scored) Oral > Solid > tablet: 50 mg (scored)	Failure or rejection of transplanted organs or tissues Relapsing-remitting multiple sclerosis

Bendamustine

Section	Indications
Cytotoxic medicines Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL	Chronic lymphocytic leukaemia or small lymphocytic lymphoma Follicular lymphoma

Bicalutamide

Section	Indications
Hormones and antihormones Oral > Solid: 50 mg	Malignant neoplasms of prostate

Binimetinib

Section	Indications
Targeted therapies	Therapeutic equivalent to trametinib for Other specified melanoma of skin

Bleomycin

Section	Indications
Cytotoxic medicines Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)	Germ cell tumour of testis Kaposi sarcoma of unspecified primary site Hodgkin lymphoma Other specified malignant neoplasms of the ovary Unspecified malignant neoplasms of ill-defined or unspecified sites

Bortezomib

Section	Indications
Targeted therapies Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection	Plasma cell myeloma

Calcium folinate (leucovorin calcium)

Section	Indications
Cytotoxic medicines Oral > Solid: 15 mg tablet Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule Oral > Solid > tablet: 15 mg; 5 mg; 25 mg	Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia Malignant neoplasm metastasis in large intestine Malignant trophoblastic neoplasms of placenta Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of rectum Malignant neoplasms of colon

Capecitabine

Section	Indications
Cytotoxic medicines Oral > Solid > tablet: 150 mg; 500 mg	Other specified malignant neoplasms of breast Malignant neoplasm metastasis in large intestine Malignant neoplasms of rectum Malignant neoplasms of colon

Carboplatin

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL	Other specified gliomas of brain Other specified carcinomas of ovary Retinoblastoma Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Malignant neoplasms of kidney, except renal pelvis Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of lip, oral cavity or pharynx Malignant neoplasms of cervix uteri Other specified malignant neoplasms of the ovary Germ cell tumour of testis

Cemiplimab

Section	Indications
Immunomodulators	Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung

Certolizumab pegol

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis

Chlorambucil

Section	Indications
Cytotoxic medicines Oral > Solid: 2 mg tablet	Unspecified malignant neoplasms of ill-defined or unspecified sites Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Ciclosporin

Section	Indications
Immunomodulators for non-malignant disease Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection Oral > Liquid: 100 mg per mL Oral > Solid > capsule: 25 mg	Failure or rejection of transplanted organs or tissues

Cisplatin

Section	Indications
Cytotoxic medicines Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL	Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified gliomas of brain Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Germ cell tumour of testis Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of lip, oral cavity or pharynx Malignant neoplasms of cervix uteri

Cladribine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial	Langerhans cell histiocytosis

Cobimetinib

Section	Indications
Targeted therapies	Therapeutic equivalent to trametinib for Other specified melanoma of skin

Crizotinib

Section	Indications
Targeted therapies Oral > Solid: 200 mg; 250 mg Oral > Solid > capsule: 200 mg; 250 mg	Other specified malignant neoplasms of bronchus or lung Anaplastic large cell lymphoma, ALK-positive

Cyclophosphamide

Section	Indications
Cytotoxic medicines Oral > Solid: 25 mg tablet Parenteral > General injections > unspecified: 500 mg in vial powder for injection Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection Oral > Solid > dosage form: 25 mg; 50 mg	Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified malignant neoplasms of breast Malignant trophoblastic neoplasms of placenta Follicular lymphoma Malignant neoplasms of breast Chronic lymphocytic leukaemia or small lymphocytic lymphoma Rhabdomyosarcoma primary site Hodgkin lymphoma Diffuse large B-cell lymphomas Plasma cell myeloma Other specified gliomas of brain Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive

Cytarabine

Section	Indications
Cytotoxic medicines Parenteral > General injections > unspecified: 100 mg in vial powder for injection Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial	Unspecified malignant neoplasms of ill-defined or unspecified sites Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Acute myeloid leukaemia with recurrent genetic abnormalities Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis

Dabrafenib

Section	Indications
Targeted therapies Oral > Solid: 50 mg; 75 mg	Other specified melanoma of skin

Dacarbazine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection	Hodgkin lymphoma

Dactinomycin

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 500 µg in vial powder for injection	Malignant trophoblastic neoplasms of placenta Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site Ewing sarcoma of bone and articular cartilage of unspecified sites

Daratumumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL	Plasma cell myeloma

Dasatinib

Section	Indications
Targeted therapies Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet	Chronic myeloid leukaemia, not elsewhere classified

Daunorubicin

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)	Acute myeloid leukaemia with recurrent genetic abnormalities Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia

Dexamethasone

Section	Indications
Hormones and antihormones Oral > Solid: 4 mg Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt) Oral > Liquid: 2 mg per 5 mL Oral > Solid: 2 mg; 4 mg	Plasma cell myeloma Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive

Docetaxel

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL	Other specified malignant neoplasms of breast Malignant neoplasms of breast Malignant neoplasms of prostate Unspecified malignant neoplasms of ill-defined or unspecified sites

Doxorubicin

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride) Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)	Unspecified malignant neoplasms of ill-defined or unspecified sites Rhabdomyosarcoma primary site Malignant neoplasms of breast Hodgkin lymphoma Diffuse large B-cell lymphomas Plasma cell myeloma Follicular lymphoma Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Anaplastic large cell lymphoma, ALK-negative Other specified malignant neoplasms of breast Anaplastic large cell lymphoma, ALK-positive Ewing sarcoma of bone and articular cartilage of unspecified sites Kaposi sarcoma of unspecified primary site

Doxorubicin (as pegylated liposomal)

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)	Kaposi sarcoma of unspecified primary site

Durvalumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 120 mg per 2.4 mL in vial; 500 mg per 10 mL in vial	Other specified malignant neoplasms of bronchus or lung

Encorafenib

Section	Indications
Targeted therapies	Therapeutic equivalent to dabrafenib for Other specified melanoma of skin

Enzalutamide

Section	Indications
Hormones and antihormones Oral > Solid: 40 mg	Therapeutic equivalent to abiraterone for Malignant neoplasms of prostate Malignant neoplasms of prostate

Erlotinib

Section	Indications
Targeted therapies Oral > Solid: 100 mg; 150 mg	Other specified malignant neoplasms of bronchus or lung

Etanercept

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis

Etoposide

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule Oral > Solid: 100 mg capsule Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate) Oral > Solid: 100 mg capsule; 50 mg capsule	Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Germ cell tumour of testis Malignant trophoblastic neoplasms of placenta Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Hodgkin lymphoma Retinoblastoma Anaplastic large cell lymphoma, ALK-positive Anaplastic large cell lymphoma, ALK-negative

Everolimus

Section	Indications
Targeted therapies Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg	Other specified gliomas of brain

Filgrastim

Section	Indications
Immunomodulators Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial	Acquired neutropaenia

Fingolimod

Section	Indications
Immunomodulators for non-malignant disease Oral > Solid: 0.25 mg; 0.5 mg	Relapsing-remitting multiple sclerosis

Fludarabine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection Oral > Solid: 10 mg tablet (fludarabine phosphate)	Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Fluorouracil

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule Parenteral > General injections > IV: 50 mg per mL in vial	Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant neoplasms of nasopharynx Malignant neoplasm metastasis in large intestine Malignant neoplasms of breast Malignant neoplasms of rectum Malignant neoplasms of colon

Flutamide

Section	Indications
Hormones and antihormones	Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate

Fulvestrant

Section	Indications
Hormones and antihormones Parenteral > General injections > IV: 250 mg per 5 mL	Malignant neoplasms of breast

Gefitinib

Section	Indications
Targeted therapies	Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung

Gemcitabine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection	Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung

Golimumab

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis

Goserelin

Section	Indications
Hormones and antihormones	Therapeutic equivalent to leuprorelin for Malignant neoplasms of breast Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate

Hydrocortisone

Section	Indications
Hormones and antihormones Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)	Lymphoid leukaemia, not elsewhere classified Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia

Hydroxycarbamide (hydroxyurea)

Section	Indications
Cytotoxic medicines Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg	Squamous cell carcinoma of oropharynx Chronic myeloid leukaemia, not elsewhere classified

Ibrutinib

Section	Indications
Targeted therapies Oral > Solid: 140 mg	Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Ifosfamide

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection	Other specified malignant neoplasms of the ovary Germ cell tumour of testis Ewing sarcoma of bone and articular cartilage of unspecified sites Osteosarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive

Imatinib

Section	Indications
Targeted therapies Oral > Solid: 100 mg; 400 mg	B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1 Gastrointestinal stromal tumour of unspecified gastrointestinal sites Chronic myeloid leukaemia, not elsewhere classified

Infliximab

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis

Irinotecan

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial	Malignant neoplasm metastasis in large intestine Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site

Lenalidomide

Section	Indications
Immunomodulators Oral > Solid: 25 mg	Plasma cell myeloma

Leuprorelin

Section	Indications
Hormones and antihormones Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe	Malignant neoplasms of breast Malignant neoplasms of prostate

Lisocabtagene maraleucel

Section	Indications
Antineoplastics and supportive medicines	Therapeutic equivalent to axicabtagene ciloleucel for Diffuse large B-cell lymphomas

Melphalan

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg in vial powder for injection Oral > Solid: 2 mg	Plasma cell myeloma

Mercaptopurine

Section	Indications
Cytotoxic medicines Oral > Solid: 50 mg tablet Oral > Liquid: 20 mg per mL	Unspecified malignant neoplasms of ill-defined or unspecified sites Acute myeloid leukaemia with recurrent genetic abnormalities Lymphoid leukaemia, not elsewhere classified Langerhans cell histiocytosis

Mesna

Section	Indications
Supportive medicines Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule Oral > Solid: 400 mg; 600 mg	Osteosarcoma of bone and articular cartilage of other specified sites Other specified malignant neoplasms of the ovary Germ cell tumour of testis Ewing sarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis

Methotrexate

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg in vial (as sodium salt) Oral > Solid: 2.5 mg (as sodium salt) Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection	Unspecified malignant neoplasms of ill-defined or unspecified sites Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Malignant trophoblastic neoplasms of placenta Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis
Immunomodulators for non-malignant disease Parenteral > General injections > SC: pre-filled syringe in multiple strengths	Crohn disease site Psoriatic arthritis

Methylprednisolone

Section	Indications
Hormones and antihormones Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)	Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia

Nilotinib

Section	Indications
Targeted therapies Oral > Solid > capsule: 150 mg; 200 mg	Chronic myeloid leukaemia, not elsewhere classified

Nilutamide

Section	Indications
Hormones and antihormones	Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate

Nivolumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion	Other specified malignant neoplasms of bronchus or lung Melanoma of skin

Osimertinib

Section	Indications
Targeted therapies Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)	Other specified malignant neoplasms of bronchus or lung

Oxaliplatin

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial	Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon

Paclitaxel

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 6 mg per mL	Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Kaposi sarcoma of unspecified primary site Other specified malignant neoplasms of breast Other specified carcinomas of ovary Malignant neoplasms of breast Malignant neoplasms of cervix uteri

Palbociclib

Section	Indications
Targeted therapies Oral > Solid: 75 mg; 100 mg; 125 mg	Other specified malignant neoplasms of breast

Pegaspargase

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection	Lymphoid leukaemia, not elsewhere classified

Pegfilgrastim

Section	Indications
Immunomodulators Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe	Acquired neutropaenia

Pembrolizumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 50 mg powder for injection	Therapeutic equivalent to nivolumab for Melanoma of skin Other specified malignant neoplasms of bronchus or lung

Pertuzumab

Section	Indications
Targeted therapies Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution	Carcinoma of breast, specialised type

Prednisolone

Section	Indications
Hormones and antihormones Oral > Liquid: 5 mg per mL Oral > Solid: 5 mg; 25 mg	Unspecified malignant neoplasms of ill-defined or unspecified sites Plasma cell myeloma Follicular lymphoma Lymphoid leukaemia, not elsewhere classified Malignant neoplasms of prostate Chronic lymphocytic leukaemia or small lymphocytic lymphoma Hodgkin lymphoma Diffuse large B-cell lymphomas Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis

Prednisone

Section	Indications
Hormones and antihormones	Therapeutic equivalent to prednisolone for Plasma cell myeloma Therapeutic equivalent to prednisolone for Follicular lymphoma Therapeutic equivalent to prednisolone for Lymphoid leukaemia, not elsewhere classified Therapeutic equivalent to prednisolone for Malignant neoplasms of prostate Therapeutic equivalent to prednisolone for Chronic lymphocytic leukaemia or small lymphocytic lymphoma Therapeutic equivalent to prednisolone for Hodgkin lymphoma Therapeutic equivalent to prednisolone for Diffuse large B-cell lymphomas Therapeutic equivalent to prednisolone for Anaplastic large cell lymphoma, ALK-negative Therapeutic equivalent to prednisolone for Anaplastic large cell lymphoma, ALK-positive Therapeutic equivalent to prednisolone for Langerhans cell histiocytosis

Procarbazine

Section	Indications
Cytotoxic medicines Oral > Solid: 50 mg (as hydrochloride) Oral > Solid > capsule: 50 mg (as hydrochloride)	Unspecified malignant neoplasms of ill-defined or unspecified sites Hodgkin lymphoma

Rasburicase

Section	Indications
Supportive medicines Parenteral > General injections > IV: 1.5 mg in vial powder and solvent for solution; 7.5 mg in vial powder and solvent for solution	Tumour lysis syndrome

Realgar-indigo naturalis formulation

Section	Indications
Cytotoxic medicines Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)	Acute myeloid leukaemia with recurrent genetic abnormalities

Ribociclib

Section	Indications
Targeted therapies	Therapeutic equivalent to palbociclib for Other specified malignant neoplasms of breast

Rituximab

Section	Indications
Targeted therapies Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial	Follicular lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphomas Burkitt lymphoma including Burkitt leukaemia

Tacrolimus

Section	Indications
Immunomodulators for non-malignant disease Parenteral > General injections > IV: 5 mg per mL in 1 mL vial Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)	Failure or rejection of transplanted organs or tissues

Tamoxifen

Section	Indications
Hormones and antihormones Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)	Other specified malignant neoplasms of breast Malignant neoplasms of breast

Thalidomide

Section	Indications
Immunomodulators Oral > Solid: 50 mg	Plasma cell myeloma

Tioguanine

Section	Indications
Cytotoxic medicines Oral > Solid: 40 mg	Lymphoid leukaemia, not elsewhere classified

Tisagenlecleucel

Section	Indications
Antineoplastics and supportive medicines	Therapeutic equivalent to axicabtagene ciloleucel for Diffuse large B-cell lymphomas

Tislelizumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 100 mg per 10 mL	Malignant neoplasms of urinary tract Hodgkin lymphoma Other specified malignant neoplasms of bronchus or lung

Toripalimab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 240 mg per 6 mL in vial	Malignant neoplasms of nasopharynx Malignant neoplasms of oesophagus

Trametinib

Section	Indications
Targeted therapies Oral > Solid: 0.5 mg; 2 mg	Other specified melanoma of skin

Trastuzumab

Section	Indications
Targeted therapies Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection	Carcinoma of breast, specialised type

Trastuzumab emtansine

Section	Indications
Targeted therapies Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection	Carcinoma of breast, specialised type

Triptorelin

Section	Indications
Hormones and antihormones	Therapeutic equivalent to leuprorelin for Malignant neoplasms of breast Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate

Vemurafenib

Section	Indications
Targeted therapies	Therapeutic equivalent to dabrafenib for Other specified melanoma of skin

Vinblastine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate) Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)	Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified gliomas of brain Kaposi sarcoma of unspecified primary site Hodgkin lymphoma Other specified malignant neoplasms of the ovary Germ cell tumour of testis Anaplastic large cell lymphoma, ALK-positive Anaplastic large cell lymphoma, ALK-negative Langerhans cell histiocytosis

Vincristine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate) Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)	Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified gliomas of brain Malignant trophoblastic neoplasms of placenta Follicular lymphoma Kaposi sarcoma of unspecified primary site Rhabdomyosarcoma primary site Hodgkin lymphoma Diffuse large B-cell lymphomas Retinoblastoma Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Langerhans cell histiocytosis

Vinorelbine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial Oral > Solid > capsule: 20 mg; 30 mg; 80 mg	Other specified malignant neoplasms of breast Other specified malignant neoplasms of bronchus or lung Rhabdomyosarcoma primary site

Zanubrutinib

Section	Indications
Targeted therapies Oral > Solid: 80 mg	Mantle cell lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Zoledronic acid

Section	Indications
Supportive medicines Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle	Malignant neoplasm metastasis in bone or bone marrow